European Journal of Human Genetics (2015) 23, 381–387
© 2015 Macmillan Publishers Limited All rights reserved 1018-4813/15
www.nature.com/ejhg

ARTICLE

Identifying genetic risk variants for coronary heart disease in familial hypercholesterolemia: an extreme genetics approach

Jorie Versmissen^{1,31}, Daniëlla M Oosterveer^{1,31}, Mojgan Yazdanpanah^{1,31}, Abbas Dehghan², Hilma Hólm³, Jeanette Erdman⁴, Yurii S Aulchenko^{2,5}, Gudmar Thorleifsson³, Heribert Schunkert⁴, Roeland Huijgen⁶, Ranitha Vongpromek¹, André G Uitterlinden^{1,2}, Joep C Defesche⁶, Cornelia M van Duijn², Monique Mulder¹, Tony Dadd⁷, Hróbjartur D Karlsson⁸, Jose Ordovas⁹, Iris Kindt¹⁰, Amelia Jarman⁷, Albert Hofman², Leonie van Vark-van der Zee¹, Adriana C Blommesteijn-Touw¹, Jaap Kwekkeboom¹¹, Anho H Liem¹², Frans J van der Ouderaa¹³, Sebastiano Calandra¹⁴, Stefano Bertolini¹⁵, Maurizio Averna¹⁶, Gisle Langslet¹⁷, Leiv Ose¹⁷, Emilio Ros^{18,19}, Fátima Almagro²⁰, Peter W de Leeuw²¹, Fernando Civeira²², Luis Masana²³, Xavier Pintó²⁴, Maarten L Simoons²⁵, Arend FL Schinkel^{1,25}, Martin R Green⁷, Aeilko H Zwinderman²⁶, Keith J Johnson²⁷, Arne Schaefer²⁸, Andrew Neil²⁹, Jacqueline CM Witteman², Steve E Humphries³⁰, John JP Kastelein⁶ and Eric JG Sijbrands^{*,1}

Mutations in the low-density lipoprotein receptor (*LDLR*) gene cause familial hypercholesterolemia (FH), a disorder characterized by coronary heart disease (CHD) at young age. We aimed to apply an extreme sampling method to enhance the statistical power to identify novel genetic risk variants for CHD in individuals with FH. We selected cases and controls with an extreme contrast in CHD risk from 17 000 FH patients from the Netherlands, whose functional *LDLR* mutation was unequivocally established. The genome-wide association (GWA) study was performed on 249 very young FH cases with CHD and 217 old FH controls without CHD (above 65 years for males and 70 years of age for females) using the Illumina HumanHap550K chip. In the next stage, two independent samples (one from the Netherlands and one from Italy, Norway, Spain, and the United Kingdom) of FH patients were used as replication samples. In the initial GWA analysis, we identified 29 independent single nucleotide polymorphisms (SNPs) with suggestive associations with premature CHD ($P < 1 \times 10^{-4}$). We examined the association of these SNPs with CHD risk in the replication samples. After Bonferroni correction, none of the SNPs either replicated or reached genome-wide significance after combining the discovery and replication samples. Therefore, we conclude that the genetics of CHD risk in FH is complex and even applying an 'extreme genetics' approach we did not identify new genetic risk variants. Most likely, this method is not as effective in leveraging effect size as anticipated, and may, therefore, not lead to significant gains in statistical power.

European Journal of Human Genetics (2015) 23, 381-387; doi:10.1038/ejhg.2014.101; published online 11 June 2014

INTRODUCTION

Coronary heart disease (CHD) is one of the leading causes of death.¹ Multiple genetic risk variants with small to moderate effects on the susceptibility to CHD have been identified in genome-wide association (GWA) studies; however, these variants explain only a small fraction of the heritable component of the risk of CHD.^{2,3}

*Correspondence: Professor EJG Sijbrands, Vascular Medicine, Erasmus Medical Centre, Dr Molewaterplein 10, Rotterdam 3015 GD, The Netherlands. Tel: +31 10 06 22569510; Fax: +31 10 703 36 39; E-mail: e.sijbrands@erasmusmc.nl

³¹These authors contributed equally to this work.

Received 5 May 2013; revised 12 April 2014; accepted 26 April 2014; published online 11 June 2014

¹Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands; ²Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands; ³deCODE Genetics, Reykjavik, Iceland; ⁴Deutsches Hertzzentrum München, Technische Universität München, München, Germany; ⁵Novosibirsk State University, Novosibirsk, Russia; ⁶Department of Vascular Medicine, Amsterdam Medical Center, Amsterdam, The Netherlands; ⁷Unilever R&D, Colworth Science Park, Sharnbrook, UK; ⁸Icelandic Heart Association and Department of Cardiology, Landspitali-University Hospital, Reykjavik, Iceland; ⁹Nutrition and Genomics Laboratory, Jean Mayer USDA HNRCA at Tufts University, Boston, MA, USA; ¹⁰Stichting Opsporing Erfelijke Hypercholesterolemie, Amsterdam, The Netherlands; ¹¹Department of Gastroenterology and Hepatology, Erasmus University Medical Centre, Rotterdam, The Netherlands; ¹²Department of Cardiology, Sint Franciscus Gasthuis Hospital, Rotterdam, The Netherlands; ¹³Netherlands Consortium for Healthy Ageing, Leiden University Medical Center, Leiden, The Netherlands; ¹⁴Department of Biomedical Sciences, University of Modena and Reggio Emilia, Modena, Italy; ¹⁵Department of Internal Medicine, University of Genova, Genova, Italy; ¹⁶Department of Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy; ¹⁷Lipid Clinic, Oslo University Hospital, Oslo, Norway; ¹⁸Lipid Clinic, Endocrinology and Nutrition Service, Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain; 19CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; 20Hospital de Guipúzcoa, San Sebastián, Guipúzcoa, España; 21Department of Internal Medicine, Maastricht University Medical Center, Maastricht, The Netherlands; 22Lipids Unit and Molecular Research Unit, Hospital Universitario Miguel Servet, Zaragoza, Spain; ²³Unitat de Recerca en Lípids i Arteriosclerosi (URLA), Hospital Universitari Sant Joan de Reus, Reus, Spain; ²⁴Unitat de Lípids i Arteriosclerosi, Servei de Medicina Interna, Hospital Universitari de Bellvitge, Barcelona, Spain; ²⁵Department of Cardiology, Erasmus University Medical Center, Rotterdam, The Netherlands; ²⁶Department of Clinical Epidemiology and Biostatistics, Amsterdam Medical Center, Amsterdam, The Netherlands; ²⁷Novartis Insitutes of Biomedical Research, Cambridge, MA, USA; ²⁸Institute of Clinical Molecular Biology, Christian-Albrechts-University, Kiel, Germany; ²⁹Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK; ³⁰Cardiovascular Genetics, BHF Laboratories, Institute Cardiovascular Science, University College London, London, UK

Therefore, many genetic variants remain to be discovered. Among the discovered genes, many are related to lipid metabolism.^{4,5} New study designs will be necessary for uncovering additional associated variants. Selecting the populations who already have high lipid levels are well suited to search for genes that increase the risk of CHD beyond dyslipidemia.⁶ Therefore, we performed a GWA study in a selected sample of familial hypercholesterolemia (FH) patients having severe hypercholesterolemia caused by mutations in the low-density lipoprotein receptor (*LDLR*) gene (MIM 143890).⁷

Traditional GWA studies are performed on extremely large sample sizes including tens of thousands of individuals.⁸ In contrast, we used an extreme genetics approach to enhance the statistical power. In this method, only the individuals with an extreme of the phenotype are genotyped. In our study, we genotyped FH patients who had CHD at very young age as cases, and elderly patients who, despite their high low-density lipoprotein (LDL) cholesterol level, had not experienced CHD as controls. We hypothesized that using this design would enhance the identification of additional genetic risk variants of CHD in FH.

MATERIALS AND METHODS

The schematic study design is shown in Figure 1. We performed the study in two stages. Stage I included a GWA study in the Dutch 'Association of CHD Risk in a Genome-wide Old-*versus*-young Setting' (ARGOS) sample. Stage II consisted of genotyping of a second case–control sample, refer to as Mutations Associated with Risk of Cardiovascular disease in volunteers with Hypercholesterolemia (MARCH) and a large FH cohort, refer to as FH Follow-up (FHFU). All patients were of Caucasian descent. In ARGOS, this was confirmed by multi-dimensional scaling of identical-by-state pairwise distances. All patients gave informed consent and the local ethics committees approved the protocol.

Description of the populations

Gene-finding stage

ARGOS. The ARGOS sample consists of 500 patients, who were selected from 17000 Dutch FH patients with a mutation in the *LDLR* gene. They were recruited in the Netherlands by the nationwide molecular screening program of the 'Stichting Opsporing Erfelijke Familiare Hypercholesterolemie?'⁹ Phenotypic data (including CHD events) were acquired from general practitioners and by reviewing medical records at the lipid and cardiologic clinics. We selected the 264 youngest patients with premature CHD and the 236 oldest patients without any CHD, stratified for sex. The maximum age of the female cases was 60 years and that of the male cases 45 years. The minimum age of the controls was 65 years for males and 70 years for females. First and second degree family members were excluded. CHD was defined as




Figure 1 Study design. Abbreviations: CHD, coronary heart disease; FH, familial hypercholesterolemia; GWA, genome-wide association; SNP, single nucleotide polymorphism.

the presence of at least one of the following: (i) myocardial infarction (MI), proved by at least two of the following: (a) classical symptoms (>15 min), (b) specific abnormalities on electrocardiography, and (c) elevated cardiac enzymes (>2× upper limit of normal); (ii) percutaneous coronary intervention or other invasive procedures; (iii) coronary artery bypass grafting (CABG). Patients with angina pectoris were excluded because in the majority of cases this diagnosis could not be assured by objective data.

MARCH. The MARCH study group consisted of 413 FH patients (190 cases, 223 controls), from Italy, Norway, Spain, and the United Kingdom. A few patients were born in another country but all were Caucasian. All patients had clinically proven FH and a mutation in either the *LDLR* or the *APOB* gene. The maximum age of the female cases was 59 and that of the male cases 45 years. The minimum age of the controls was 50 years for males and 60 for females. For the cases in this cohort, the same CHD definition was applied as described above for the ARGOS sample with the addition of (iv) angina pectoris (AP), as this phenotype was accurately addressed in this cohort. AP was diagnosed as classical symptoms in combination with at least one unequivocal positive result of one of the following: (a) exercise test, (b) nuclear scintigram, (c) dobutamine stress ultrasound, or (d) >70% stenosis on a coronary angiogram. The controls had no manifest CHD.

FHFU study. The second replication cohort consisted of Dutch clinically proven heterozygous FH patients who were recruited from 27 lipid clinics in the Netherlands between 1989 and 2002.^{10,11} For the cases in this cohort, the same CHD definition was applied as described above for the MARCH sample. The controls had no manifest CHD. The DNA of 2073 unrelated patients was available for the present analysis. A total of 51 FH patients had already been included in the ARGOS sample and were, therefore, removed from the FHFU group, leaving 2022 DNA samples for analyses.

Additional cohorts. In addition to these three FH cohorts, selected single nucleotide polymorphisms (SNPs) were also genotyped in population-based cohorts that have been described in detail previously: The Rotterdam Study (n = 5207, a cohort of elderly inhabitants of a suburb of Rotterdam, from which we selected patients with prevalent CHD to ascertain that CHD occurred at relatively young age; 777 CHD cases), deCODE (n = 12848, selected from the national Islandic deCODE database; 726 cases with premature MI) and GerMIFSII (n = 2520, a German cohort with 1222 proven MI cases before the age of 60).^{12–14}

Genotyping in ARGOS

The samples of participants of the ARGOS group were assayed with Illumina Infinium HumanHap550K Chips (Illumina, San Diego, CA, USA) at Erasmus University Medical Center in Rotterdam, the Netherlands. Samples were processed according to the Illumina Infinium II manual. In brief, each sample was whole-genome amplified, fragmented, precipitated, and resuspended in the appropriate hybridization buffer. After hybridization, these denatured samples were processed for the single-base extension reaction and were stained and imaged on an Illumina Bead Array Reader. Normalized bead-intensity data obtained for each sample were loaded into the Illumina Beadstudio software where the fluorescent intensities were converted into SNP genotypes. Using Quanto software (http://biostats.usc.edu/software) considering ARGOS as a conventional case–control study and assuming large effect sizes owing to only genotyping the phenotypic extremes, we estimated that had >80% statistical power to detect effect sizes >2.5 at a genome-wide significant level and than 1.46 for a *P*-value threshold of 0.05.

Genotyping frequencies have been deposited at the European Genomephenome Archive (EGA, http://www.ebi.ac.uk/ega/) which is hosted at the EBI, under accession number EGAS00001000734. The genotyping data are also available via the Dutch Biobanking and Biomolecular Research Infrastructure (https://catalogue.bbmri.nl/biobanks/, accession number 199).

Quality-control filtering

After genome-wide genotyping, a call-rate threshold above 98% was used for inclusion of the samples. Subjects were excluded from the sample if their sex was inconsistent with genetic data from the X chromosome and if duplicate samples produced inconsistent genotypes. SNPs were excluded if they had

(i) successful genotyping in <90% of the cases and controls, (ii) a minor allele frequency <1% in the population, (iii) showed deviation from Hardy–Weinberg equilibrium (P-value <0.0001), or (iv) were monomorphic across all samples. After these exclusions, 535 179 SNPs remained.

Genotyping in MARCH and FHFU

In MARCH and FHFU, the genotypes of selected SNPs were determined using fluorescence-based TaqMan allelic discrimination assays and analyzed on an ABI Prism 7900 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). Reaction components and amplification parameters were based on the manufacturer's instructions using an annealing temperature of 60 °C. Results were scored blinded to CHD status. SNPs were excluded following the same quality criteria as in the gene-finding stage.

Statistical analysis

The genomic inflation factor was calculated using the mean of the χ^2 -tests generated on all SNPs that were tested. For each SNP which passed the quality control in the ARGOS population, the association with risk of CHD was examined in an additive genetic model using a logistic regression model adjusted for sex. Given the fact that age was an inclusion criterion to generate the contrast between cases and controls of the ARGOS population, we did not adjust for age.

We selected all SNPs that were associated with CHD with a *P*-value $<\!1.00\times10^{-4}$ in ARGOS to analyze in the second stage. In the second stage, the association with risk of CHD was examined using logistic regression in MARCH and the FHFU. In MARCH, we adjusted for sex only, as age was a selection criterion similar to ARGOS. In the FHFU cohort, we adjusted for age, sex, and statin use, as statin use was expected to be a confounder and, in contrast to ARGOS and MARCH, it was well documented in that cohort. Using Bonferroni correction, significance threshold was 0.0017 (0.05/29). We performed a z-based meta-analysis to combine the results of MARCH and FHFU in the second stage. Furthermore, we combined the results of all three studies using z-based meta-analysis.

We used Plink version 1.03 to run GWA study in ARGOS, SPSS version 15 to run logistic regression models in MARCH and FHFU and finally 'meta' and 'rmeta' packages running under R to perform the meta-analysis.^{15–17}

Replication of well-known SNPs associated with CHD

To test the effect of earlier defined genetic risk variants on CHD in ARGOS, we analyzed the SNPs described in a large-scale meta-analysis in the CARDIO-GRAM consortium (22 233 cases and 64 762 controls). Whenever the SNP was not available on the IlluminaHap550, we used a proxy as identified by SNAP (http://www.broadinstitute.org/mpg/snap/ldsearchs.php).

RESULTS

Characteristics of the ARGOS cohort

Out of 17 000 Dutch FH patients with a known *LDLR* mutation, we selected the 264 youngest FH patients with CHD and the 236 oldest FH patients without any CHD. The mean \pm SD (range) age was 41.7 \pm 8.3 (23–59 years) in cases and 75.6 \pm 5.9 (65–years) in controls. A total of 249 cases and 217 controls were successfully genotyped. There were no significant differences in age, smoking, or plasma cholesterol levels between the patients who were and those who were not successfully genotyped (data not shown). General characteristics of the genotyped patients are shown in Table 1 and the age distribution in Supplementary Figure 1.

Eighty-one cases (32.5%) had a negative *LDLR* mutation, for example, a mutation leading to complete loss of function of the LDL receptor, whereas only 42 controls (19.4%) had a receptor-negative mutation (P = 0.004). This was mainly due to an overrepresentation of the c.1359-1G>A mutation, which was present in 46 cases and only in 21 controls. The other mutations were equally distributed (Supplementary Table 1). On average, the controls were 34 years older than the cases (P-value < 0.001). Consequently, hypertension and diabetes mellitus were more often present in the controls than in the cases. More cases than controls were ever smokers (Table 1).

Stage I (GWA analysis)

After quality-control filtering, we included 535 179 SNPs in the GWA analysis. A quantile–quantile plot of the observed against expected *P*-value distribution is shown in Figure 2. The genomic inflation factor (λ gc) was 1.01 in the total sample. Supplementary Figure 2 illustrates the primary findings from the GWA analysis in the ARGOS population and presents *P*-values for each of the interrogated SNPs across the chromosomes. For a total of 40 SNPs clustered around 21 loci on all chromosomes except 3, 6, 12, 15, 16, and 18–21 the *P*-value was lower than the threshold of 1×10^{-4} (Table 2). Of these, 11 were in complete linkage disequilibrium (LD) with a leading SNP in the same locus. Twelve out of 40 SNPs were located in a cluster on chromosome 11p15; they were located in four different LD blocks and could be tagged by six SNPs. We took 29 SNPs, including the 6 SNPs in11p15, to stage II.

Table 1 Characteristics of the ARGO	S population and the	replication populations
-------------------------------------	----------------------	-------------------------

					Diabetes		
Population	Ν	Males (%)	Age (years)	Smoking (%)	Mellitus (%)	Hypertension (%)	Total Cholesterol (mmol/l)
Stage I: genome-wi	ide analysis						
ARGOS							
CHD cases	249	55.0	41.7 ± 8.4^{a}	74.2 ^a	2.4ª	19.7ª	11.3 ± 2.6^{a}
Controls	217	47.9	75.6 ± 5.9^{a}	51.2ª	9.2ª	30.0 ^a	10.6 ± 2.8^{a}
Stage II: replication	n						
MARCH							
CHD cases	190	63.2	39.4±7.4	49.5 ^b	10.0	36.3	11.0 ± 2.2^{a}
Controls	223	60.1	63.6±9.2	47.1 ^b	11.2	34.5	10.5±1.7ª
FHFU							
CHD cases	554	65.5ª	48.9 ± 10.6^{a}	83.0 ^a	4.8ª	16.7ª	9.5 ± 2.1
Controls	1468	43.5ª	46.6 ± 12.7^{a}	70.3 ^a	1.7ª	6.0 ^a	9.4 ± 1.9

Abbreviations: CHD, coronary heart disease; N, number of participants.

Continuous variables are given as mean \pm SD.

 ^{a}P <0.05 for the difference between CHD cases and controls within the cohort. b Cases and controls were matched for smoking in the MARCH Study.

384

Stage II

We successfully genotyped 28 SNPs in MARCH and all 29 SNPs in FHFU (Supplementary Table 2). For none of the SNPs, the *P*-value was lower than the Bonferroni corrected threshold of 0.017 either in MARCH or FHFU. The smallest *P*-value was found for rs176388 (odds ratio OR 0.33, P = 0.042) in MARCH. Although the direction of the effect was the same in FHFU, the association was not significant (OR 0.80, P = 0.36). We performed a meta-analysis to combine the results of the analysis in MARCH and FHFU. None of the SNPs




Figure 2 QQ Plot.

reached the Bonferroni significant threshold after combining the results of MARCH and FHFU.

Finally, we combined the results of ARGOS, MARCH, and FHFU; however, none of the top SNPs identified in ARGOS reached the genome-wide significance level. The smallest combined *P*-value was 4×10^{-4} for rs176388, for which the A allele showed a protective effect in all cohorts. Second best was rs1380945, for which all cohorts showed that the G allele was associated with increased CHD risk (Table 3 and Supplementary Figure 3).

Genotyping additional cohorts from the general population did not show any genome-wide significance.

Replication of well-known SNPs associated with CHD in the general population

To examine if the genetic risk variants identified in GWA studies in the general population also showed an effect in ARGOS and to test whether effect sizes were larger in our 'extreme genetics' population, we examined the association of 25 previously reported genetic risk factors in CARDIoGRAM. In this meta-analysis, 9 out of 12 previously reported CHD loci were confirmed with a *P*-value of $<5.0 \times 10^8$ and 13 new ones identified (Table 4).⁵ None of the studied SNPs were significantly associated with CHD in ARGOS. Lowest *P*-values were obtained for rs4977574 at 9p21 (CARDIoGRAM OR 1.29, 95% CI 1.23–1.36; $P = 1.35 \times 10^{-22}$;

Table 2 SNPs influencing coronary heart	lisease risk in the ARGOS	5 population (with $P < 1.0 \times 10^{-4}$)
---	---------------------------	---

SNP	Chr	Position	Accession number	Reference allele	Alternate allele	SNP type	Gene	Freq cases	Freq controls	OR	95% CI	P-value
	0111	1 OSILION	number	uncie	ancie	onn type	ache	00000	00111013	On	55% 01	1 Value
rs12087224	1p22	83 902 972	NT_032977.8	G	А	Intergenic	TTLL7	0.15	0.06	2.54	1.59–4.04	8.86×10^{-5}
rs7581691	2p24	13 953 005	NT_005334.15	G	A	—	—	0.16	0.07	2.62	1.67-4.11	2.93×10^{-5}
rs1406333	2q32	184 155 187	NT_005403.16	A	G	Intergenic	NUP35	0.33	0.47	0.59	0.45-0.77	8.23×10^{-5}
rs2412397	4q12	53 804 380	NT_022853.14	A	G	Intronic	SCFD2	0.31	0.44	0.57	0.43-0.76	$9.98 imes 10^{-5}$
rs778940	4q13	62 926 680	NT_022778.15	A	G	Intergenic	LPHN3	0.16	0.07	2.44	1.57–3.77	$6.74 imes 10^{-5}$
rs6835823	4q32	155 191 807	NT_016354.18	A	С	Intergenic	DCHS2	0.48	0.37	1.77	1.36-2.30	2.11×10^{-5}
rs4696207	4q32	155 488 838	NT_016354.18	С	А	Intronic	DCHS2	0.50	0.36	1.80	1.36-2.38	$3.36 imes10^{-5}$
rs7691894	4q32	167 900 239	NT_022792.17	А	G	Intronic	SPOCK3	0.39	0.23	2.06	1.53-2.77	$1.74 imes10^{-6}$
rs11950716	5p15.2	14 141 834	NT_006576.15	G	А	Intergenic	TRIO	0.14	0.25	0.51	0.36-0.71	$9.45 imes 10^{-5}$
rs17638888	7q22	98 335 561	NT_007933.14	G	А	Intronic	TRRAP	0.03	0.09	0.27	0.14-0.51	5.89×10^{-5}
rs12544799	8q24.2	130 732 692	NT_008046.15	А	G	Intergenic	MLZE	0.41	0.28	1.87	1.40-2.50	2.53×10^{-5}
rs6985166	8q24.2	130 748 358	NT_008046.15	А	G	Intergenic	MLZE	0.38	0.26	1.81	1.35–2.43	7.81×10^{-5}
rs13291498	9p21	28 326 185	NT_008413.17	А	С	Intronic	LINGO2	0.21	0.33	0.55	0.41-0.73	5.44×10^{-5}
rs10761805	10q21	65 294 147	NT_008583.16	G	A	Intergenic	REEP3	0.49	0.35	1.89	1.42-2.51	1.36×10^{-5}
rs955353	10q21	65 314 593	NT_008583.16	G	А	_	_	0.37	0.50	0.57	0.43-0.75	7.20×10^{-5}
rs2111995	10q25	107 497 352	NT_030059.12	А	G	Intergenic	SORCS3	0.28	0.17	1.97	1.42-2.72	4.10×10^{-5}
rs2647547	11p15	5 359 744	NT_009237.17	А	С	Intergenic	OR51M1	0.46	0.33	1.75	1.33–2.31	5.85×10^{-5}
rs1532514	11p15	5 373 198	NT_009237.17	С	А	Intergenic	OR51M1	0.48	0.38	1.71	1.32-2.23	6.37×10^{-5}
rs10838092	11p15	5 400 443	NT_009237.17	G	А	Exonic	OR51Q1	0.45	0.31	1.73	1.32-2.26	6.73 × 10 ⁻⁵
rs10838102	11p15	5 414 207	NT_009237.17	G	А	Intergenic	OR5111	0.46	0.32	1.78	1.36–2.33	3.06×10^{-5}
rs1498486	11p15	5 418 567	NT_009237.17	А	С	Exonic	OR5111	0.48	0.34	1.81	1.38–2.38	2.02×10^{-5}
rs2133235	11p15	5 423 352	NT_009237.17	С	А	Intergenic	OR5111	0.44	0.30	1.82	1.28-2.40	2.27×10^{-5}
rs2846186	11q25	134 203 586	NT_033899.7	А	G	Intergenic	B3GAT1	0.18	0.30	0.50	0.36-0.68	1.18×10^{-5}
rs2661969	11q25	134 223 427	NT_033899.7	А	G	Intergenic	B3GAT1	0.18	0.29	0.54	0.39–0.73	9.16×10^{-5}
rs1380945	13q13	31 739 619		А	G	Intronic	FRY	0.48	0.35	1.74	1.32-2.30	9.76×10^{-5}
rs4982548	14q11	21 605 911	_ NT_026437.11	G	А	Intergenic	OR4E2	0.43	0.57			2.43×10^{-5}
rs2531851	17p13	9 141 140	_ NT_010718.15	G	А	Intronic	STX8	0.40	0.27	1.92	1.43–2.59	1.40×10^{-5}
rs5755595	22q12	33 848 839		G	А	Intergenic	RAXLX	0.38	0.26	1.84	1.36–2.48	6.28 × 10 ⁻⁵
rs5928090	Xp21	32 780 853	NT 011757.15	A	G	_	_	0.42	0.27	1.75	1.18-2.60	4.20 × 10 ⁻⁵

Abbreviations: CI, confidence interval; Chr, chromosome; Freq, frequency; OR, odds ratio; SNP, single nucleotide polymorphism. Chromosome base position according to NCBI Genome build 36.3. Intergenic is defined as <500 Mb from the gene.

Table 3 Results of the genome-wide as	ssociation study in the two FH	replication populations
---------------------------------------	--------------------------------	-------------------------

		MARCH	/ (n = 413)	FHFU (N = 2022)	Meta-analysis	MARCH+ FHFU	Meta-analysis AF	GOS+MARCH + FHFU
SNP	Risk allele	OR	P-value	OR	P-value	OR	P-value	OR	P-value
rs12087224	А	1.01	0.96	1.06	0.70	1.04	0.73	1.27	$3.1 imes 10^{-2}$
rs7581691	А	1.07	0.79	0.86	0.35	0.91	0.51	1.20	$1.2 imes 10^{-1}$
rs1406333	G	0.98	0.89	0.96	0.71	0.98	0.68	0.84	1.5×10^{-2}
rs2412397	G	NA	NA	0.91	0.36	NA	NA	NA	NA
rs778940	G	0.86	0.53	1.29	0.06	1.16	0.17	1.35	2.9×10^{-3}
rs6835823	С	1.07	0.63	0.94	0.66	1.01	0.93	1.24	$8.4 imes10^{-3}$
rs4696207	А	0.90	0.48	1.10	0.33	1.03	0.70	1.19	$1.4 imes10^{-2}$
rs7691894	G	1.02	0.99	1.03	0.74	1.02	0.80	1.20	$1.2 imes 10^{-2}$
rs11950716	А	0.83	0.35	0.94	0.60	0.91	0.34	0.78	5.8×10^{-3}
rs17638888	А	0.52	0.04	0.80	0.36	0.69	0.05	0.54	2.0×10^{-4}
rs12544799	G	1.06	0.70	0.94	0.52	0.98	0.77	1.14	$7.6 imes 10^{-2}$
rs6985166	G	1.05	0.76	1.09	0.38	1.08	0.36	1.22	$6.4 imes 10^{-3}$
rs13291498	С	0.92	0.62	1.22	0.06	1.12	0.21	0.92	$2.9 imes10^{-1}$
rs10761805	А	1.05	0.76	1.00	0.99	1.01	0.87	1.18	2.2×10^{-2}
rs955353	А	0.88	0.36	1.01	0.91	0.97	0.67	0.85	$1.9 imes10^{-2}$
rs2111995	G	0.81	0.22	1.14	0.23	1.03	0.74	1.20	$2.3 imes10^{-2}$
rs2647547	С	0.98	0.90	1.04	0.67	1.02	0.79	1.17	$2.4 imes10^{-2}$
rs1532514	А	1.04	0.79	1.01	0.88	1.02	0.81	1.16	$2.6 imes10^{-2}$
rs10838092	А	1.09	0.59	1.00	0.96	1.02	0.80	1.18	$2.4 imes10^{-2}$
rs10838102	А	1.20	0.21	0.96	0.70	1.03	0.71	1.19	$1.5 imes10^{-2}$
rs1498486	С	1.11	0.45	1.07	0.51	1.08	0.34	1.23	3.1×10^{-3}
rs2133235	А	1.20	0.22	1.93	0.48	1.01	0.93	1.17	$2.5 imes 10^{-2}$
rs2846186	G	0.83	0.26	1.06	0.63	0.97	0.76	0.81	$1.1 imes10^{-2}$
rs2661969	G	0.83	0.23	0.97	0.97	0.91	0.35	0.79	4.9×10^{-3}
rs1380945	G	1.25	0.13	1.14	0.19	1.17	0.06	1.29	$3.0 imes10^{-4}$
rs4982548	А	1.02	0.89	1.07	0.45	1.05	0.48	0.91	$1.7 imes10^{-1}$
rs2531851	А	1.07	0.63	0.89	0.23	0.95	0.51	1.11	$1.4 imes10^{-1}$
rs5755595	А	0.80	0.15	0.90	0.33	0.86	0.10	1.05	5.4×10^{-1}
rs5928090	G	1.04	0.73	0.95	0.54	0.98	0.73	1.08	$2.3 imes 10^{-1}$

Abbreviation: OR, odds ratio.

Combined *P*-value given for replication populations.

ARGOS OR 1.28, 95% CI 1.00–1.67; P = 0.05) and for the SNP in the proprotein convertase subtilisin/kexin type 9 (*PCSK9*) gene that did not show genomic significance in CARDIOGRAM (CARDIOGRAM OR 1.08, 95% CI 1.05–1.11; $P = 9.1 \times 10^{-8}$; ARGOS OR 1.52, 95% CI 1.10–2.12, P = 0.01).

DISCUSSION

In this study, by using an extreme genetics approach, we aimed to fortify our statistical power to identify novel genetic risk variants for CHD. However, none of the suggestive findings were either confirmed in the second stage or reached the genome-wide significant threshold in a meta-analysis of all populations combined.

We expected to identify larger effect sizes in our GWA study, compared with traditional GWA studies on CHD, for two reasons. First, we studied genetic risk variants for CHD in a cohort of FH patients, and hypercholesterolemia is one of the most important risk factors for CHD. Based on Rothman's model of causation, one would expect that in the presence of similar environmental factors, risk variants in genes will be associated with larger outcome effects.⁶ Second, we applied an extreme selection approach. Therefore, the genetic contrast between cases and controls was expected to increase.¹⁸ This incremental contrast has been shown to increase the power in simulation studies in quantitative traits. The effect sizes found when selectively genotyping only the phenotypic extremes will be increased.^{18–20} Plomin suggested that common disorders could

also be considered as quantitative traits, as risk on a common disease in the population could be regarded as a distribution of 'polygenetic liability' to a disease. The extreme sampling approach should, therefore, produce larger effect sizes in our study as well. Thus, the power was expected to be relatively high, despite the reduction in number of individuals as a result of the selection criteria.^{18,19,21} Our study is the first to apply this method using real data. Using Quanto, we confirmed that the study was sufficiently powered to identify risk variants with large effect sizes in this high-risk group of subjects. Our findings, being more specific our odds ratios, indicate that the leverage in effect size using this approach is, in fact, quite modest. This is also clear from the data from CARDIoGRAM in our study, as an example, the well-replicated locus at 9p21.3 had an OR of 1.28, very close to the 1.25 value that was found in the original study of subjects from the general population. Most other known CHD risk SNPs identified in earlier studies and published by Schunkert *et al*⁵ were not associated with statistically significant effects in this FH sample. However, our study was underpowered for this analysis if the true effect sizes were the same as reported and less increased by our design than anticipated, so we can only look at the direction of the effect. Out of 18 SNPs that could be tested, 11 ORs were in the same direction, whereas only 6 were not (Table 4). Of these 11, most interesting was the SNP in PCSK9. This SNP is associated with an 8% higher risk of CHD in the general population; however, the odds in ARGOS were increased by >50%. Although the P-value in

Table 4 Results of earlier identified genetic risk factors in ARGOS⁵

						CA	RDIoGRAM				
		Gene(s) in	Accession	Ref.	Risk allele						
SNP	Chr	region	number	allele	(frequency)	OR	P-value	Genotyped	Proxy ^a	0R ^b	P-value
rs11206510	1p32.3	PCSK9	NT_032977.9	С	T (0.82)	1.08	$9.1 imes10^{-8}$	Yes		1.52	0.01
rs17114036 ^c	1p32.2	PPAP2B	NT_039277.8	G	A (0.91)	1.17	2.2×10^{-6}	No	rs9970807	0.87	0.56
rs599839	1p13.3	SORT1	NT_019273.18	G	A (0.78)	1.11	2.9×10^{-10}	No	rs646776	1.00	0.99
rs17465637	1q41	MIA3	NT_021877.18	А	C (0.74)	1.14	1.4×10^{-8}	No	No proxy		
rs6725887	2q33.1	WDR12	NT_005403.16	Т	C (0.15)	1.14	1.1×10^{-9}	Yes		1.07	0.76
rs2306374	3q22.3	MRAS	NT_005612.15	Т	C (0.18)	1.12	3.3×10^{-8}	Yes		0.96	0.81
rs12526453	6p24.1	PHACTR1	NT_007592.14	G	C (0.67)	1.10	1.2×10^{-9}	No	rs4714990	1.03	0.8
rs17609940 ^c	6p21.31	ANKS1A	NT_007592.14	С	G (0.75)	1.07	2.2×10^{-6}	No	rs820082	0.83	0.25
rs12190287 ^c	6q23.2	TCF21	NT_025741.14	G	C (0.62)	1.08	4.6×10^{-11}	No	No proxy		
rs3798220	6q25.3	LPA	NT_007422.13	Т	C(0.02)	1.09	3.0×10^{-11}	No	No LD data		
rs11556924 ^c	7q32.2	ZC3HC1	NT_007933.14	Т	C (0.62)	1.09	2.2×10^{-9}	No	No proxy		
rs4977574	9p21.3	CDKN2A, CDKN2B	NT_008413.17	А	G (0.46)	1.25	1.4×10^{-22}	Yes		1.28	0.05
rs579459 ^c	9q34.2	ABO	NT_035014.4	Т	C (0.21)	1.10	1.2×10^{-7}	No	rs495828	1.35	0.08
rs1746048	10q11.21	CXCL12	NT_033985.6	Т	C (0.87)	1.33	2.9×10^{-10}	Yes		1.41	0.1
rs12413409 ^c	10q24.32	CYP17A1, CNNM2, NT5C2	NT_030059.12	А	G (0.89)	1.12	1.5×10^{-6}	Yes		1.23	0.36
rs964184 ^c	11q23.3	ZNF259, APOA5-A4-C3-A1	NT_03899.8	С	G (0.13)	1.13	8.0×10^{-10}	No	No proxy		
rs3184504	12q24.12	SH2B3	NT_033899.7	С	T (0.44)	1.13	6.4×10^{-6}	Yes		1.01	0.96
rs4773144 ^c	13q34	COL4A1, COL4A2	NT_009952.14	А	G (0.44)	1.07	4.2×10^{-7}	No	No proxy		
rs2895811 ^c	14q32.2	HHIPL1	NT_026437.11	Т	C (0.43)	1.07	2.7×10^{-7}	Yes		1.05	0.72
rs3825807 ^c	15q25.1	ADAMTS7	NT_01094.16	G	A (0.57)	1.08	9.6×10^{-6}	No	rs7177699	NA	NA
rs216172 ^c	17p13.3	SMG6, SRR	NT_010718.15	G	C (0.37)	1.07	$6.2 imes10^{-7}$	No	rs2281727	0.85	0.26
rs12936587 ^c	17p11.2	RASD1, SMCR3, PEMT	NT_010718.15	А	G (0.56)	1.07	4.9×10^{-7}	No	rs11871738	0.83	0.14
rs46522 ^c	17q21.32	UBE2Z, GIP, ATP5G1, SNF8	NT_010783.14	С	T (0.53)	1.06	3.6×10^{-6}	No	rs962272	1.04	0.73
rs1122608	19p13.2	LDLR	NT_011295.10	Т	G (0.77)	1.14	9.7×10^{-10}	No	rs3786725	0.81	0.17
rs9982601	21q22.11	MRPS6	NT_011512.10	С	T (0.15)	1.18	4.2×10^{-10}	No	rs7278204	1.28	0.19

Abbreviation: Ref., reference.

Chromosome position according to NCBI Genome build 36.3. ^aUsing SNAP (http://www.broadinstitute.org/mpg/snap/ldsearchs.php).

^bRisk allele or representative proxy. ^cOR representing combined analysis CARDIoGRAM & replication cohort.⁵

CARDIoGRAM did not reach genome-wide significance, it is tempting to speculate that this finding and the enhanced effect in ARGOS is not due to chance, but might reflect an interaction between this gene and cholesterol levels. PCSK9 is a gene encoding proprotein convertase subtilisin/kexin type 9, involved in the intracellular degradation of LDL receptors. PCSK9 levels correlated inversely with LDL cholesterol levels in FH patients.²² PCSK9 inhibitors are being tested in phase III trials²³ now, and are expected to be highly effective in FH patients.^{24,25}

Our definition of extreme groups might have been too restrictive, as it constitutes a very small proportion of the FH sample (500 out of 17000).

Nevertheless, our findings may help to understand why genetic risk prediction models have not yet succeeded. In our approach, we attempted to identify novel genes by selecting the extreme groups of the CHD risk distribution spectrum. Genetic risk prediction studies, on the other hand, start with genetic information and estimate who will end up in the low- and the high-risk group.²⁶ As we could demonstrate that the effect sizes in this design are not as enlarged as we expected, the contrast needed for prediction might be less than anticipated as well: genetic risk factors most likely have a more gradual distribution over the population instead of being over- or underrepresented in the phenotypic extremes and the combination of classical and genetic risk factors defines the CHD risk.

Our approach has a number of limitations. Finding extreme cases is a challenging effort. Although FH is a relatively common genetic

disorder, collecting a large sample of subjects either with early onset CHD or healthy aging is difficult. The low genomic inflation factor (1.01) in the total sample indicated that population admixture was not likely.²⁷ We do realize that from a statistical point of view our sample size was not enough to detect genes with small effects. Another issue might be whether difference in age between cases and controls might bring in extra confounding. Although only Caucasian patients were studied, first and second degree family members were excluded and we had phenotypic data, we cannot exclude the presence of an unknown confounder. A last limitation of a GWA study in FH subjects is that the results may not necessarily apply to the general population.²⁸ Results may be restricted to FH patients or to hypercholesterolemic patients in general. Also, it might be possible that CHD risk in the young is genetically different from CHD risk at an older age.

We conclude that the genetics of CHD risk in FH is complex and even applying an 'extreme genetics' approach, we did not identify new genetic risk variants. Most likely, this method is not as effective in leveraging effect size as anticipated, and may, therefore, not lead to significant gains in statistical power. Also, this study might explain why genetic risk prediction modeling is yielding disappointment. The odds ratio associated with genetic variation at the PCSK9 locus points to important consequences for PCSK9 activity in FH patients and provides hope for the novel approach to lower these levels through monoclonal antibodies in order to prevent CHD.

CONFLICT OF INTEREST

Professor Kastelein is a recipient of the Lifetime Achievement Award of the Dutch Heart Foundation. Keith J Johnson was an employé of Pfizer in Groton, CT, USA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. All other authors declare no conflict of interest.

ACKNOWLEDGEMENTS

We thank Carl Jarman and David Gunn for help in sample preparation and data collection. CIBERobn is an initiative of ISCIII, Spain. This work was supported by the Dutch Heart Foundation (2006B190) and Unilever, UK. Additional funding was provided by Pfizer and MSD The Netherlands. SEH acknowledges BHF support (RG 2008/008) and also funding from the Department of Health's NIHR Biomedical Research Centre funding scheme. ER is supported by grant FIS PS09/01292 from ISCIII, Spain.

- 1 Rosamond W, Flegal K, Furie K *et al*: Heart disease and stroke statistics–2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation* 2008; **117**: e25–146.
- 2 Peden JF, Farrall M: Thirty-five common variants for coronary artery disease: the fruits of much collaborative labour. *Hum Mol Genet* 2011; 20: R198–R205.
- 3 So HC, Gui AH, Cherny SS, Sham PC: Evaluating the heritability explained by known susceptibility variants: a survey of ten complex diseases. *Genet Epidemiol* 2011; 35: 310–317.
- 4 Kathiresan S, Voight BF, Purcell S et al: Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet 2009; 41: 334–341.
- 5 Schunkert H, Konig IR, Kathiresan S *et al*: Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. *Nat Genet* 2011; **43**: 333–338.
- 6 Rothman KJ, Greenland S: Causation and causal inference in epidemiology. *Am J Public Health* 2005; **95**:Suppl 1 S144–S150.
- 7 Hobbs HH, Brown MS, Goldstein JL: Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. *Hum Mutat* 1992; 1: 445–466.
- 8 McCarthy MI, Abecasis GR, Cardon LR et al: Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 2008; 9: 356–369.
- 9 Umans-Eckenhausen MA, Defesche JC, Scheerder RL, Cline F, Kastelein JJ: [Tracing of patients with familial hypercholesterolemia in the Netherlands]. *Ned Tijdschr Geneeskd* 1999; **143**: 1157–1161.

- 10 Jansen AC, van Aalst-Cohen ES, Hutten BA, Buller HR, Kastelein JJ, Prins MH: Guidelines were developed for data collection from medical records for use in retrospective analyses. J Clin Epidemiol 2005; 58: 269–274.
- 11 Jansen AC, van Aalst-Cohen ES, Tanck MW *et al*: The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. *J Int Med* 2004; **256**: 482–490.
- 12 Hofman A, Breteler MM, van Duijn CM *et al*: The Rotterdam Study: 2010 objectives and design update. *Eur J Epidemiol* 2009; **24**: 553–572.
- 13 Helgadottir A, Thorleifsson G, Manolescu A *et al*: A common variant on chromosome 9p21 affects the risk of myocardial infarction. *Science* 2007; **316**: 1491–1493.
- 14 Erdmann J, Grosshennig A, Braund PS et al: New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet 2009; 41: 280–282.
- 15 Purcell S, Neale B, Todd-Brown K *et al*: PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 2007; 81: 559–575.
- 16 Schwarzer G: The Meta Package. www.cranr-projectorg/src/contrib/Descriptions/rmetahtml 2005.
- Lumley T: The rmeta package. http://wwwcranr-projectorg/src/contrib/Descriptions/ rmetahtml 2004.
- 18 Van Gestel S, Houwing-Duistermaat JJ, Adolfsson R, van Duijn CM, Van Broeckhoven C: Power of selective genotyping in genetic association analyses of quantitative traits. *Behav Genet* 2000; **30**: 141–146.
- 19 Xing C, Xing G: Power of selective genotyping in genome-wide association studies of quantitative traits. *BMC Proc* 2009; **3**(Suppl 7): S23.
- 20 Huang BE, Lin DY: Efficient association mapping of quantitative trait loci with selective genotyping. Am J Hum Genet 2007; 80: 567–576.
- 21 Plomin R, Haworth CM, Davis OS: Common disorders are quantitative traits. Nat Rev Genet 2009; 10: 872–878.
- 22 Huijgen R, Fouchier SW, Denoun M et al: Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia. J Lipid Res 2012; 53: 979–983.
- 23 Blom DJ, Hala T, Bolognese M et al: A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809–1819.
- 24 Cohen JC, Boerwinkle E, Mosley Jr TH, Hobbs HH: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354: 1264–1272.
- 25 Sjouke B, Kusters DM, Kastelein JJ, Hovingh GK: Familial hypercholesterolemia: present and future management. *Curr Cardiol Rep* 2011; **13**: 527–536.
- 26 Ioannidis JP: Prediction of cardiovascular disease outcomes and established cardiovascular risk factors by genome-wide association markers. *Circ Cardiovasc Genet* 2009; 2: 7–15.
- 27 Devlin B, Roeder K: Genomic control for association studies. *Biometrics* 1999; 55: 997–1004.
- 28 Van der Net JB, Oosterveer DM, Versmissen J et al: Replication study of 10 genetic polymorphisms associated with coronary heart disease in a specific high-risk population with familial hypercholesterolemia. Eur Heart J 2008; 29: 2195–2201.

Supplementary Information accompanies this paper on European Journal of Human Genetics website (http://www.nature.com/ejhg)